Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999 implications for primary prevention

Circulation

Volumn 108, Issue 6, 2003, Pages 711-716

  Wattigney, Wendy A ^a   Mensah, George A ^b   Croft, Janet B ^b  

^a AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Arrhythmia; Atrial flutter; Cardiovascular diseases; Morbidity

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COMORBIDITY; DEMOGRAPHY; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES NEEDS AND DEMAND; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PNEUMONIA; PREVALENCE; SEX DISTRIBUTION; UNITED STATES;

EID: 0043164965     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000083722.42033.0A     Document Type: Article

References (37)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implication. Arch bacterial Med. 1995;155:469-473.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
3. Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation: risk marker for stroke. N Engl J Med. 1990;323:1556-1558.
4. Fisher CM. Embolism in atrial fibrillation. In: Kulbertus HE. Olsson SB, Sclepper M, eds. Atrial fibrillation: proceedings of a symposium held in Kiruna, Sweden, June 24-27. 1981. Molndal. Sweden: Hassle: 1982:192-210.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
6. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
7. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical cost. Arch Intern Med. 1998;158:229-234.
8. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
9. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840-844.
10. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol. 2002;155:819-826.
11. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalization of older Americans for cardiac conduction disorders of arrhythmias, 1991-1998. J Am Geriatr Soc. 2001;49:763-770.
12. Frost L, Engholm G, Moller H, et al. Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980-1993. Eur Heart J. 1999;20:1592-1599.
13. Stewart S, MacIntyre K, MacLeod MM, et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J. 2001;22:693-701.
14. Frost L, Johnsen SP, Pedersen L, et al. Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology. 2002;13:211-215.
15. National Center for Health Statistics. International Classification of Diseases, 9th Revision, Clinical Modification. Washington, DC: Public Health Service; 1980. Available at: http://www.cdc.gov/nchs/icd9.htm. Accessed July 16, 2003.
16. Simmons WR, Schnack GA. Development of the design of the NCHS Hospital Discharge Survey. Vital Health Stat. series 2. Available at: http://www.cdc.gov/nchs/data/series/sr_02/sr02_039pdf. Accessed July 16, 2003.
17. Haupt B, Kozak LJ. Estimates from two survey designs: National Hospital Discharge Survey. Vital Health Stat. 1992;13:1-75.
18. Dennison CF, Pokras R. Design and operation of the National Hospital Discharge Survey: 1988 redesign. Available at: http://www.cdc.gov/nchs/ data/series/sr_01/st01_39.pdf.
19. Klein RJ, Schoenborn CA. Age Adjustment Using the 2000 Projected US Population. Healthy People Statistical Notes, No. 20. Hyattsville. Md: National Center for Health Statistics; 2001.
20. Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352-360.
21. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999;84:131R-138R.
22. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521-523.
23. Popovic JR. 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2001;151:1-206.
24. Hindricks G, Mohr FW, Autschbach R, et al. Antiarrhythmic surgery for treatment of atrial fibrillation: new concepts. Thorac Cardiovasc Surg. 1999;47(suppl 3):365-369.
25. Ng FS, Camm AJ. Catheter ablation of atrial fibrillation. Clin Cardiol. 2002;25:384-394.
26. Copper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med. 2002;346:2062-2068.
27. Krol RB, Saksena S, Prakash A. New devices and hybrid therapies for treatment of atrial fibrillation. J Interv Card Electrophysiol. 2000;(suppl 1):163-169.
28. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
29. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
30. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
31. SPAF-II Study Investigators, Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343:687-691.
32. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-1412.
33. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-355.
34. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262,
35. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-1277.
36. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern. Med. 1998;158:1669-1677.
37. Heim SW. Cost-effectiveness of atrial fibrillation therapy. J Fam Pract. 1998;47:334-335.